This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Neurology				
Ataxia	Enhancer of zeste homolog 2 (EZH2)	<p><i>In vitro</i> and mouse studies suggest inhibiting EZH2 could help treat ataxia telangiectasia. In <i>ataxia telangiectasia mutated (Atm)</i>-deficient mice, intracerebellar injection of lentiviruses expressing Ezh2 small hairpin RNA decreased neuronal cell death compared with injection of lentiviruses expressing control shRNA and improved ataxic behavioral abnormalities. Next steps include testing either EZH2 inhibition in the model or a combination of drugs that depress histone methylation while enhancing acetylation. Epizyme Inc. and Eisai Co. Ltd. have EPZ6438 (E7438), a selective inhibitor of EZH2, in Phase I/II testing to treat lymphoma and non-Hodgkin's lymphoma (NHL).</p> <p>Constellation Pharmaceuticals Inc., Novartis AG and GlaxoSmithKline plc have EZH2 inhibitors in preclinical development to treat cancer.</p> <p>SciBX 6(45); doi:10.1038/scibx.2013.1299 Published online Nov. 21, 2013</p>	Findings unpatented; unavailable for licensing	<p>Li, J. <i>et al. Nat. Neurosci.</i>; published online Oct. 27, 2013; doi:10.1038/nn.3564</p> <p>Contact: Karl Herrup, The Hong Kong University of Science and Technology, Hong Kong, China e-mail: herrup@ust.hk</p> <p>Contact: Jiali Li, Rutgers University, Piscataway, N.J. e-mail: jli@dls.rutgers.edu</p>